Gauthier Mouillet1, Nicolas Lellouche1, Masanori Yamamoto1, Atsushi Oguri1, Jean-Luc Dubois-Rande1, Eric Van Belle2, Martine Gilard3, Marc Laskar4, Emmanuel Teiger1. 1. Cardiology Department, Hôpital Henri Mondor, Assistance Publique Hôpitaux De Paris & INSERM U 955, Creteil, France. 2. Cardiology Department, Centre Hospitalier Universitaire De Lille, Lille, France. 3. Cardiology Department, Centre Hospitalier Universitaire De Brest, Hôpital De La Cavale Blanche, Brest, France. 4. Cardiac Surgery Unit, Centre Hospitalier Universitaire De Limoges, Cedex, France.
Abstract
AIMS: Permanent pacemaker (PPM) implantation following high-degree atrioventricular block is frequently required after transcatheter aortic valve implantation (TAVI) using CoreValve(®) . Recent improvement of the delivery system (CoreValve Accutrak(®) ) aimed to ease delivery and reduce the PPM rate. Our study evaluated the incidences of PPM implantation following use of CoreValve(®) or CoreValve Accutrak(®) and the clinical outcome of these patients. METHODS AND RESULTS: A total of 883 patients (82 ± 7 years; 41.3% female) with severe symptomatic aortic stenosis and self-expanding bioprosthesis implantation were included between January 2010 and October 2011 in 29 centers from the FRANCE 2 Registry. Follow-up data were available in 833 patients. CoreValve(®) and CoreValve Accutrak(®) were used in 343 (41.2%) and 490 (58.8%) patients, respectively. During a mean follow-up of 242 ± 179 days, all-cause mortality was similar in patients with versus without PPM implantation (16.3 vs. 16.9%, P = 0.832).There was no significant difference in the PPM incidence in CoreValve(®) and CoreValve Accutrak(®) patients (30.4% vs. 27.5%, P = 0.846). CONCLUSION: PPM implantation remained frequent after TAVI using CoreValve Accutrak(®) . All-cause mortality was similar in patients with or without PPM implantation. The new device failed to show a significant decrease in PPM implantation incidence after TAVI.
AIMS: Permanent pacemaker (PPM) implantation following high-degree atrioventricular block is frequently required after transcatheter aortic valve implantation (TAVI) using CoreValve(®) . Recent improvement of the delivery system (CoreValve Accutrak(®) ) aimed to ease delivery and reduce the PPM rate. Our study evaluated the incidences of PPM implantation following use of CoreValve(®) or CoreValve Accutrak(®) and the clinical outcome of these patients. METHODS AND RESULTS: A total of 883 patients (82 ± 7 years; 41.3% female) with severe symptomatic aortic stenosis and self-expanding bioprosthesis implantation were included between January 2010 and October 2011 in 29 centers from the FRANCE 2 Registry. Follow-up data were available in 833 patients. CoreValve(®) and CoreValve Accutrak(®) were used in 343 (41.2%) and 490 (58.8%) patients, respectively. During a mean follow-up of 242 ± 179 days, all-cause mortality was similar in patients with versus without PPM implantation (16.3 vs. 16.9%, P = 0.832).There was no significant difference in the PPM incidence in CoreValve(®) and CoreValve Accutrak(®) patients (30.4% vs. 27.5%, P = 0.846). CONCLUSION: PPM implantation remained frequent after TAVI using CoreValve Accutrak(®) . All-cause mortality was similar in patients with or without PPM implantation. The new device failed to show a significant decrease in PPM implantation incidence after TAVI.
Authors: Christian Frerker; Kurt Bestehorn; Michael Schlüter; Maike Bestehorn; Christian W Hamm; Helge Möllmann; Hugo A Katus; Karl-Heinz Kuck Journal: Clin Res Cardiol Date: 2017-03-10 Impact factor: 5.460
Authors: Birgid Gonska; Julia Seeger; Mirjam Keßler; Alexander von Keil; Wolfgang Rottbauer; Jochen Wöhrle Journal: Clin Res Cardiol Date: 2017-03-10 Impact factor: 5.460
Authors: Christiana Schernthaner; Johannes Kraus; Franz Danmayr; Matthias Hammerer; Jens Schneider; Uta C Hoppe; Bernhard Strohmer Journal: Wien Klin Wochenschr Date: 2016-01-08 Impact factor: 1.704
Authors: Talal Aljabbary; Feng Qiu; Shannon Masih; Jiming Fang; Gabby Elbaz-Greener; Peter C Austin; Josep Rodés-Cabau; Dennis T Ko; Sheldon Singh; Harindra C Wijeysundera Journal: JAMA Netw Open Date: 2018-05-18